Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

首次发布于 2015 年 1 月 14 日

Phase I Norovirus Challenge Model

计划入组 48 人 · 首次发布于 2019 年 11 月 22 日

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

计划入组 44 人 · 首次发布于 2015 年 6 月 16 日

Norovirus GI.4/GII.4 Bivalent VLP Vaccine (Icon Genetics GmbH)

Norovirus bivalent vaccine (Takeda)

Norovirus GI.1/GII.4 Bivalent Virus-like Particle(Takeda)

HilleVax

United States

Vaxart

United States

IGI Laboratories

United States

Cocrystal Pharma's Antiviral CDI-988 Shows Potent Activity Against Emerging Norovirus Variants

Cocrystal Pharma Advances First Oral Norovirus Antiviral CDI-988 into Phase 1b Human Challenge Study

Airplane Wastewater Surveillance Detects SARS-CoV-2 Variants Weeks Before Clinical Systems